A panelist discusses how benign prostatic hyperplasia (BPH) treatment has evolved to include a spectrum of minimally invasive and surgical interventions, ranging from emerging technologies like ...

“The benefit of being here at the University of Minnesota is that we have a bunch of different types of settings to be able to trial this," says Hailey Frye. A study from the American Urological ...

Recent advancements in kidney stone management include novel access sheaths and miniaturized scopes, enhancing treatment options for patients. AI integration in kidney stone management offers ...

“I feel a lot of providers, with Antiva being available, have unfortunately reserved use of this great FDA-approved agent for BCG-unresponsive patients because of the supply issue with BCG," says ...

A panelist discusses how Matching-Adjusted Indirect Comparison (MAIC) analyses are limited by potential unmeasured confounding factors, small effective sample sizes after matching, and reliance on ...

A panelist discusses how MAIC (Matching-Adjusted Indirect Comparison) methodology addresses the lack of head-to-head clinical trials in metastatic hormone-sensitive prostate cancer (mHSPC) by ...

"What we found is that 9% of women with a GSM-related diagnosis filled a prescription for vaginal estrogen during the study period, and these women tended to be younger," says Ekene Enemchukwu, MD, ...

Minimal WVTT with one treatment per lobe showed fewer post-operative complications and similar efficacy compared to multiple treatments per lobe. The study included 146 patients, with comparable ...

Looking forward, do you believe novel delivery systems in NMIBC could be easily adopted in clinical practices? What challenges do you anticipate in operationalizing TAR-200 and other novel delivery ...

Experts discuss the unmet needs in the treatment of non–muscle-invasive bladder cancer (NMIBC), highlighting areas where advancements are still needed.

Betty Wang, MD, provides insight on 3 presentations that she believes “may be game changing” in urology. The 40th Annual European Association of Urology Congress in Madrid, Spain, featured an ...

A polygenic risk score identified more clinically significant prostate cancer cases than PSA or MRI in the BARCODE1 trial. The study involved 6393 participants, with 745 invited for screening based on ...